AgNovos Healthcare, LLC
9
3
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 9 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
Role: lead
RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures
Role: lead
RISE - Study of the AGN1 LOEP SV Kit in Patients With Vertebral Compression Fractures
Role: lead
RECONFIRM - Study of AGN1 LOEP in Patients with Osteoporosis
Role: lead
CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP
Role: lead
Copley II: Long-term Outcome Follow-up Study of Osteoporotic Women Who Underwent a Local Osteo-Enhancement Procedure (LOEP) in the Proximal Femur
Role: lead
GRACE - Study of AGN1 LOEP in Osteopenic and Osteoporotic Patients
Role: lead
STRONG - Study of AGN1 LOEP for the Treatment of the Contralateral Femur After Fragility Fracture
Role: lead
CONFIRM - Study of AGN1 LOEP in Patients With Osteoporosis
Role: lead
All 9 trials loaded